David S. Wolf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David S. Wolf has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth J. Cohen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
2 shared publications - Nadja Kadom
From the Department of Radiology and Imaging Sciences (N.K., N.L., A.C.), Emory University School of Medicine, Atlanta, Georgia
2 shared publications - Ammar Kheder
Department of Neurology, Emory University School of Medicine , Atlanta, GA 30322 , USA
1 shared publication Anna Trofimova
Department of Radiology and Imaging Sciences, Emory University School of Medicine, 201 Dowman Dr, Atlanta, GA 30322
1 shared publicationBernard A. Cohen
Division of Pediatric Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publicationBrianna L. Vey
Emory University School of Medicine, Atlanta, GA
1 shared publication
Latest Publications
- 26 February 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 107, 1-3
Possible underlying mechanism of epileptic nystagmus as studied by stereoelectroencephalography
- 26 February 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 107, 1-3
Possible underlying mechanism of epileptic nystagmus as studied by stereoelectroencephalography
Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex
- 1 February 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (2)
Congenital Toxoplasmosis Presenting as Eosinophilic Encephalomyelitis With Spinal Cord Hemorrhage
A 4-week-old male neonate with a history of intermittent hypothermia in the newborn nursery presented with an acute onset of bilateral lower extremity paralysis and areflexia. Extensive workup demonstrated eosinophilic encephalomyelitis and multifocal hemorrhages of the brain and spinal cord. Funduscopic examination revealed bilateral chorioretinitis with macular scarring. The laboratory values were notable for peripheral eosinophilia and cerebrospinal fluid eosinophilic pleocytosis (28 white blood cells/µL, 28% eosinophils), markedly elevated protein (1214 mg/dL), and hypoglycorrhachia (20 mg/dL). Toxoplasma gondii immunoglobulin M (IgM) test result was positive. Reference testing obtained at the Palo Alto Medical Foundation Toxoplasma Serology Laboratory confirmed the diagnosis of congenital toxoplasmosis in the infant with a positive immunoglobulin G (IgG) dye test result, immunoglobulin A enzyme-linked immunosorbent assay, and IgM immunosorbent agglutination assay. The diagnosis of an infection acquired during gestation in the mother was established by a positive maternal IgG dye test result, IgM enzyme-linked immunosorbent assay, immunoglobulin A, immunoglobulin E, and low IgG avidity. At 6-month follow-up, the infant had marginal improvement in his retinal lesions and residual paraplegia with hyperreflexia and clonus of the lower extremities. A repeat MRI demonstrated interval development of encephalomalacia with suspected cortical laminar necrosis and spinal cord atrophy in the areas of previous hemorrhage. Clinicians should be aware of this severe spectrum of congenital toxoplasmosis disease and should remain vigilant for subtler signs that may prompt earlier testing, diagnosis, and treatment.
- 1 February 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (2)
Congenital Toxoplasmosis Presenting as Eosinophilic Encephalomyelitis With Spinal Cord Hemorrhage
A 4-week-old male neonate with a history of intermittent hypothermia in the newborn nursery presented with an acute onset of bilateral lower extremity paralysis and areflexia. Extensive workup demonstrated eosinophilic encephalomyelitis and multifocal hemorrhages of the brain and spinal cord. Funduscopic examination revealed bilateral chorioretinitis with macular scarring. The laboratory values were notable for peripheral eosinophilia and cerebrospinal fluid eosinophilic pleocytosis (28 white blood cells/µL, 28% eosinophils), markedly elevated protein (1214 mg/dL), and hypoglycorrhachia (20 mg/dL). Toxoplasma gondii immunoglobulin M (IgM) test result was positive. Reference testing obtained at the Palo Alto Medical Foundation Toxoplasma Serology Laboratory confirmed the diagnosis of congenital toxoplasmosis in the infant with a positive immunoglobulin G (IgG) dye test result, immunoglobulin A enzyme-linked immunosorbent assay, and IgM immunosorbent agglutination assay. The diagnosis of an infection acquired during gestation in the mother was established by a positive maternal IgG dye test result, IgM enzyme-linked immunosorbent assay, immunoglobulin A, immunoglobulin E, and low IgG avidity. At 6-month follow-up, the infant had marginal improvement in his retinal lesions and residual paraplegia with hyperreflexia and clonus of the lower extremities. A repeat MRI demonstrated interval development of encephalomalacia with suspected cortical laminar necrosis and spinal cord atrophy in the areas of previous hemorrhage. Clinicians should be aware of this severe spectrum of congenital toxoplasmosis disease and should remain vigilant for subtler signs that may prompt earlier testing, diagnosis, and treatment.
- Open Access
- 9 May 2019
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (6) , E32
Reply:
We appreciate that Guerrini-Rousseau and colleagues are raising awareness for constitutional mismatch repair deficiency (CMMRD) syndrome and its phenotypical overlap with neurofibromatosis type 1 (NF-1). All 5 patients described in our article met clinical criteria for NF-1 ([Table][1]). None of the
- 9 May 2019
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (6) , E32
Open AccessReply:
We appreciate that Guerrini-Rousseau and colleagues are raising awareness for constitutional mismatch repair deficiency (CMMRD) syndrome and its phenotypical overlap with neurofibromatosis type 1 (NF-1). All 5 patients described in our article met clinical criteria for NF-1 ([Table][1]). None of the
- 1 January 2018
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 210 (1) , 8-17
Imaging of Children With Nontraumatic Headaches
OBJECTIVE. Headache in children is a common symptom and often is worrisome for clinicians and parents because of the breadth of possible underlying significant abnormalities, including meningitis, brain neoplasms, and intracranial hemorrhage. For this reason, many children with headaches undergo neuroimaging. Most neuroimaging studies performed of children with headaches have normal findings but may lead to significant downstream effects, including unnecessary exposure to ionizing radiation or sedation, as well as unnecessary cost to the health care system. In this article, we review the current evidence and discuss the role of neuroimaging in the diagnosis and management of pediatric headaches, with a special focus on tools that may aid in increasing the rate of positive findings, such as classification systems, algorithms, and red flag criteria. CONCLUSION. Many tools exist that can help in improving the appropriateness of neuroimaging in pediatric headache. The main issues that remain to be addressed i...
- 1 January 2018
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 210 (1) , 8-17
Imaging of Children With Nontraumatic Headaches
OBJECTIVE. Headache in children is a common symptom and often is worrisome for clinicians and parents because of the breadth of possible underlying significant abnormalities, including meningitis, brain neoplasms, and intracranial hemorrhage. For this reason, many children with headaches undergo neuroimaging. Most neuroimaging studies performed of children with headaches have normal findings but may lead to significant downstream effects, including unnecessary exposure to ionizing radiation or sedation, as well as unnecessary cost to the health care system. In this article, we review the current evidence and discuss the role of neuroimaging in the diagnosis and management of pediatric headaches, with a special focus on tools that may aid in increasing the rate of positive findings, such as classification systems, algorithms, and red flag criteria. CONCLUSION. Many tools exist that can help in improving the appropriateness of neuroimaging in pediatric headache. The main issues that remain to be addressed i...
- 15 September 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (6) , 475-480
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2
Background Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas, meningiomas, and spinal ependymomas. There have been anecdotal reports of radiographic response of spinal ependymomas in NF2 patients being treated for progressive vestibular schwannomas with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF). Aims The aim of this study was to review the clinical effects of bevacizumab treatment for symptomatic, NF2‐associated ependymomas Methods We conducted a retrospective review of all patients with NF2 treated with bevacizumab for symptomatic ependymoma at three NF2 specialty centers. Tumor size was evaluated by linear measurements; radiographic response was defined as >20% reduction in tumor size. We also performed immunohistochemical evaluation of NF2‐associated symptomatic ependymomas from five patients, including two from this clinical series. Results Eight patients with NF2 and symptomatic ependymoma were treated with bevacizumab. All patients had subjective clinical improvement with bevacizumab, although only five of eight patients evaluated had radiographic response. All tumors expressed VEGF‐R2. Four of five evaluated ependymomas expressed VEGF‐R1; one without VEGF‐R1 expression was from a patient who showed clinical but not radiographic response. Conclusions Treatment using bevacizumab improved symptoms related to NF2‐associated ependymomas, often without concurrent radiographic response. This treatment effect may be related to VEGF‐R1 expression in NF2‐associated ependymoma.
- 15 September 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (6) , 475-480
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2
Background Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas, meningiomas, and spinal ependymomas. There have been anecdotal reports of radiographic response of spinal ependymomas in NF2 patients being treated for progressive vestibular schwannomas with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF). Aims The aim of this study was to review the clinical effects of bevacizumab treatment for symptomatic, NF2‐associated ependymomas Methods We conducted a retrospective review of all patients with NF2 treated with bevacizumab for symptomatic ependymoma at three NF2 specialty centers. Tumor size was evaluated by linear measurements; radiographic response was defined as >20% reduction in tumor size. We also performed immunohistochemical evaluation of NF2‐associated symptomatic ependymomas from five patients, including two from this clinical series. Results Eight patients with NF2 and symptomatic ependymoma were treated with bevacizumab. All patients had subjective clinical improvement with bevacizumab, although only five of eight patients evaluated had radiographic response. All tumors expressed VEGF‐R2. Four of five evaluated ependymomas expressed VEGF‐R1; one without VEGF‐R1 expression was from a patient who showed clinical but not radiographic response. Conclusions Treatment using bevacizumab improved symptoms related to NF2‐associated ependymomas, often without concurrent radiographic response. This treatment effect may be related to VEGF‐R1 expression in NF2‐associated ependymoma.
- 28 March 2014
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 30 (1) , 100-106
High-Dose Glucocorticoid Therapy in the Management of Seizures in Neonatal Incontinentia Pigmenti
Incontinentia pigmenti is an X-linked dominant disorder resulting from a mutation of IKBKG. This disorder has a classic dermatologic presentation, but neurologic involvement, with seizures and cortical infarction, can arise shortly after birth. There are no specific therapies available for the manifestations of incontinentia pigmenti. Here, we describe the clinical, electrographic, and neuroradiologic effect of systemic glucocorticoid therapy in a neonate with incontinentia pigmenti manifesting an epileptic encephalopathy. Treatment with dexamethasone led to a dramatic reduction in seizure activity and improvement in bullous lesions. A novel mutation in IKBKG is also reported.
- 28 March 2014
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 30 (1) , 100-106
High-Dose Glucocorticoid Therapy in the Management of Seizures in Neonatal Incontinentia Pigmenti
Incontinentia pigmenti is an X-linked dominant disorder resulting from a mutation of IKBKG. This disorder has a classic dermatologic presentation, but neurologic involvement, with seizures and cortical infarction, can arise shortly after birth. There are no specific therapies available for the manifestations of incontinentia pigmenti. Here, we describe the clinical, electrographic, and neuroradiologic effect of systemic glucocorticoid therapy in a neonate with incontinentia pigmenti manifesting an epileptic encephalopathy. Treatment with dexamethasone led to a dramatic reduction in seizure activity and improvement in bullous lesions. A novel mutation in IKBKG is also reported.
- 14 May 2013
- Published by Taylor & Francis in CNS Oncology
- Vol. 2 (3) , 211-213
Is low and slow the way to go? Metronomic therapy in the treatment of pediatric brain tumors
- 14 May 2013
- Published by Taylor & Francis in CNS Oncology
- Vol. 2 (3) , 211-213
Is low and slow the way to go? Metronomic therapy in the treatment of pediatric brain tumors
- 1 March 2013
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 19 (1) , 127-131
Vascular Distribution of Glioblastoma Multiforme at Diagnosis
Treatment of high-grade gliomas with selective intra-arterial (IA) administration of chemotherapies has been proposed, and utilized as a therapeutic modality. This approach offers the conceptual benefit of providing maximal delivery of the agent to the tumor bed, while potentially reducing systemic exposure to the agent. This retrospective study was designed to determine the vascular distribution of glioblastoma multiforme (GBM) at the time of diagnosis in an effort to determine what proportion of patients would likely be candidates for this approach. The preoperative MRI scans of 50 patients with GBM were analyzed and compared to published normative data of intracranial vascular distribution. Vascular distribution was determined by analyzing post-gadolinium axial and coronal T1 images, axial T2 images, and axial T2 images with an additional 1 cm margin (T2 + 1 cm) added in all dimensions. T1 analysis demonstrated 60% of tumors in a single vascular distribution. T2 analysis of these tumors reduced that number to 34%. When the T2 + 1 cm margin was utilized, only 6% of tumors were in a single vascular distribution. 66% of tumors were limited to the anterior circulation on T1 imaging but only 34% on T2 + 1 cm imaging. 30% of tumors were also within the distribution of the anterior choroidal artery. These findings suggest that the use of selective IA administration of agents is necessarily limited to a fraction of presenting patients or will require administration via multiple cerebral arteries.
- 1 March 2013
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 19 (1) , 127-131
Vascular Distribution of Glioblastoma Multiforme at Diagnosis
Treatment of high-grade gliomas with selective intra-arterial (IA) administration of chemotherapies has been proposed, and utilized as a therapeutic modality. This approach offers the conceptual benefit of providing maximal delivery of the agent to the tumor bed, while potentially reducing systemic exposure to the agent. This retrospective study was designed to determine the vascular distribution of glioblastoma multiforme (GBM) at the time of diagnosis in an effort to determine what proportion of patients would likely be candidates for this approach. The preoperative MRI scans of 50 patients with GBM were analyzed and compared to published normative data of intracranial vascular distribution. Vascular distribution was determined by analyzing post-gadolinium axial and coronal T1 images, axial T2 images, and axial T2 images with an additional 1 cm margin (T2 + 1 cm) added in all dimensions. T1 analysis demonstrated 60% of tumors in a single vascular distribution. T2 analysis of these tumors reduced that number to 34%. When the T2 + 1 cm margin was utilized, only 6% of tumors were in a single vascular distribution. 66% of tumors were limited to the anterior circulation on T1 imaging but only 34% on T2 + 1 cm imaging. 30% of tumors were also within the distribution of the anterior choroidal artery. These findings suggest that the use of selective IA administration of agents is necessarily limited to a fraction of presenting patients or will require administration via multiple cerebral arteries.
- 1 May 2012
- Published by Elsevier in The Journal of Pediatrics
- Vol. 160 (5) , 725-731
Moving from PANDAS to CANS
- 1 May 2012
- Published by Elsevier in The Journal of Pediatrics
- Vol. 160 (5) , 725-731
Moving from PANDAS to CANS